# Ikonisys

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ikonisys

- Industry: Medical Devices & Equipment
- Headquarters: New Haven, US
- Website: www.ikonisys.com
- Total disclosed funding: $41M
- Latest round: Series H (Jul 20, 2012)
- Investors on record: 6

## About

Ikonisys, Inc. is a Connecticut-based company specializing in advanced diagnostic solutions for cancer detection and monitoring, providing innovative tools that enhance cellular analysis for healthcare professionals.Founded in 1999 by Michael Kilpatrick, Ikonisys, Inc. operates from New Haven, Connecticut, and focuses on the development of diagnostic systems for cytology and pathology. The company has engaged in eight funding deals, with the latest PIPE round raising EUR 0.50 mn in July 2021, targeting investments from Cambria Ltd. Ikonisys has not undergone significant changes in business operations or structure.Ikonisys specializes in advanced diagnostic solutions, focusing on cytology and pathology for cancer detection and monitoring. Their flagship product, Ikoniscope, is an imaging platform that integrates advanced digital microscopy with proprietary software to enhance cellular analysis efficiency. This system supports clinical laboratories by enabling quicker, informed decisions for pathologists and oncologists, addressing challenges in cancer diagnostics. Ikonisys serves a diverse client base, including hospitals and diagnostics labs across North America, Europe, and select markets in Asia.In the most recent fiscal year, Ikonisys reported revenue of EUR 650,052.70, with an EBITDA of EUR -1,485,206.20. The company generates revenue through direct sales of its Ikoniscope system and service agreements, establishing long-term relationships with healthcare institutions through B2B transactions.Ikonisys, Inc. plans to utilize its recent funding from the July 2021 PIPE round to support the development of new diagnostic products and expand into new markets. The company is focused on enhancing its imaging systems and aims to enter targeted markets in Europe and Asia by 2023. This strategic growth will be supported by the ongoing commitment to innovative solutions in cancer detection and monitoring.

## Funding rounds

- Series H, Jul 20, 2012, $1.4M — Trevi Health Ventures
- Series E, Oct 17, 2007, $30M — WHI Capital Partners, Trevi Health Ventures, Goldman Sachs Asset Management, New Science Ventures, Palisade Capital Management
- Series D, Mar 8, 2006, $10M — WHI Capital Partners, Trevi Health Ventures, New Science Ventures, Lakeview Capital Management

## Investors

- WHI Capital Partners (https://capitalatlas.ai/funds/whi-capital-partners) — Series D, Series E
- Trevi Health Ventures (https://capitalatlas.ai/funds/trevi-health-ventures) — Series D, Series E, Series H
- New Science Ventures (https://capitalatlas.ai/funds/new-science-ventures) — Series D, Series E
- Lakeview Capital Management — Series D
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series E
- Palisade Capital Management (https://capitalatlas.ai/funds/palisade-capital-management) — Series E